XENETIC BIOSCIENCES, INC. (XBIO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
38/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseXBIO / S&P 8.58% / 15.20% |
WinXBIO / S&P 33.30% / 15.00% |
LoseXBIO / S&P -42.00% / 50.40% |
| 2026-Q12/3 |
WinXBIO / S&P 23.50% / -4.33% |
WinXBIO / S&P 23.52% / 11.30% |
LoseXBIO / S&P -49.58% / 27.70% |
| 2025-Q41/3 |
LoseXBIO / S&P -30.89% / 2.65% |
WinXBIO / S&P 19.04% / 9.00% |
LoseXBIO / S&P -38.13% / 13.40% |
| 2025-Q31/3 |
LoseXBIO / S&P -19.90% / 8.12% |
WinXBIO / S&P 13.30% / 4.61% |
LoseXBIO / S&P -22.93% / 13.45% |
| 2025-Q21/3 |
WinXBIO / S&P 50.19% / 10.94% |
LoseXBIO / S&P -2.94% / 4.83% |
LoseXBIO / S&P -34.85% / 10.63% |
| 2025-Q11/3 |
LoseXBIO / S&P -34.59% / -4.27% |
WinXBIO / S&P 5.63% / 4.98% |
LoseXBIO / S&P -18.77% / 10.57% |
| 2024-Q40/3 |
LoseXBIO / S&P -7.64% / 2.41% |
LoseXBIO / S&P -1.56% / 5.25% |
LoseXBIO / S&P -5.17% / 6.15% |
| 2024-Q32/3 |
WinXBIO / S&P 6.14% / 5.89% |
WinXBIO / S&P 7.15% / 5.89% |
LoseXBIO / S&P -8.59% / 6.11% |
| 2024-Q23/3 |
WinXBIO / S&P 7.96% / 4.28% |
WinXBIO / S&P 16.79% / 5.38% |
WinXBIO / S&P 10.43% / 5.12% |
| 2024-Q11/3 |
LoseXBIO / S&P 9.28% / 10.56% |
WinXBIO / S&P 27.09% / 5.71% |
LoseXBIO / S&P -26.57% / 5.59% |
| 2023-Q41/3 |
LoseXBIO / S&P -29.59% / 11.69% |
WinXBIO / S&P 48.80% / 6.81% |
LoseXBIO / S&P -23.66% / 7.78% |
| 2023-Q33/3 |
WinXBIO / S&P 49.44% / -3.27% |
WinXBIO / S&P 51.68% / 7.52% |
WinXBIO / S&P 6.99% / -5.03% |
| 2023-Q22/3 |
LoseXBIO / S&P -19.24% / 8.74% |
WinXBIO / S&P 45.07% / 9.50% |
WinXBIO / S&P 21.40% / -8.57% |
| 2023-Q13/3 |
WinXBIO / S&P 42.46% / 7.50% |
WinXBIO / S&P 41.61% / 10.77% |
WinXBIO / S&P 667.31% / -15.69% |
| 2022-Q41/3 |
LoseXBIO / S&P -46.93% / 7.56% |
WinXBIO / S&P 47.06% / 11.88% |
LoseXBIO / S&P XBIO unavailable / -17.99% |
| 2022-Q31/3 |
LoseXBIO / S&P -32.96% / -4.88% |
WinXBIO / S&P 58.52% / 13.47% |
LoseXBIO / S&P XBIO unavailable / -1.41% |
| 2022-Q21/3 |
LoseXBIO / S&P -21.47% / -16.10% |
WinXBIO / S&P 99.38% / 13.71% |
LoseXBIO / S&P XBIO unavailable / 11.04% |
| 2022-Q11/3 |
LoseXBIO / S&P -20.93% / -4.60% |
WinXBIO / S&P 137.74% / 15.97% |
LoseXBIO / S&P XBIO unavailable / 42.23% |
| 2021-Q41/3 |
LoseXBIO / S&P -37.07% / 11.03% |
WinXBIO / S&P 165.64% / 15.00% |
LoseXBIO / S&P XBIO unavailable / 96.40% |
| 2021-Q31/3 |
LoseXBIO / S&P 0.49% / 0.58% |
WinXBIO / S&P 223.59% / 10.77% |
LoseXBIO / S&P XBIO unavailable / 69.42% |
| 2021-Q21/3 |
LoseXBIO / S&P -6.42% / 8.55% |
WinXBIO / S&P 299.53% / 6.58% |
LoseXBIO / S&P XBIO unavailable / 51.81% |
| 2021-Q12/3 |
WinXBIO / S&P 6.86% / 6.17% |
WinXBIO / S&P 674.11% / -1.06% |
LoseXBIO / S&P XBIO unavailable / 7.39% |
| 2020-Q42/3 |
WinXBIO / S&P 125.41% / 12.15% |
WinXBIO / S&P 2460.31% / -3.72% |
LoseXBIO / S&P XBIO unavailable / -33.42% |
| 2020-Q30/3 |
LoseXBIO / S&P -11.27% / 8.93% |
LoseXBIO / S&P XBIO unavailable / -2.04% |
LoseXBIO / S&P XBIO unavailable / -27.10% |
| 2020-Q21/3 |
WinXBIO / S&P 37.65% / 20.54% |
LoseXBIO / S&P XBIO unavailable / -0.46% |
LoseXBIO / S&P XBIO unavailable / -27.11% |
| 2020-Q10/3 |
LoseXBIO / S&P -48.54% / -19.60% |
LoseXBIO / S&P XBIO unavailable / 3.47% |
LoseXBIO / S&P XBIO unavailable / -14.75% |
| 2019-Q41/3 |
WinXBIO / S&P 20.30% / 9.07% |
LoseXBIO / S&P XBIO unavailable / 5.36% |
LoseXBIO / S&P XBIO unavailable / 2.99% |
| 2019-Q30/3 |
LoseXBIO / S&P -89.36% / 1.70% |
LoseXBIO / S&P XBIO unavailable / 5.02% |
LoseXBIO / S&P XBIO unavailable / 0.21% |
| 2019-Q20/3 |
LoseXBIO / S&P -51.68% / 4.30% |
LoseXBIO / S&P XBIO unavailable / 6.64% |
LoseXBIO / S&P XBIO unavailable / 8.65% |
| 2019-Q11/3 |
WinXBIO / S&P 18.29% / 13.65% |
LoseXBIO / S&P XBIO unavailable / 8.12% |
LoseXBIO / S&P XBIO unavailable / 14.29% |
| 2018-Q40/3 |
LoseXBIO / S&P -42.05% / -13.52% |
LoseXBIO / S&P XBIO unavailable / 9.05% |
LoseXBIO / S&P XBIO unavailable / 18.23% |
| 2018-Q30/3 |
LoseXBIO / S&P -30.64% / 7.71% |
LoseXBIO / S&P XBIO unavailable / 10.21% |
LoseXBIO / S&P XBIO unavailable / 19.06% |
| 2018-Q21/3 |
WinXBIO / S&P 89.77% / 3.43% |
LoseXBIO / S&P XBIO unavailable / 9.03% |
LoseXBIO / S&P XBIO unavailable / 14.46% |
| 2018-Q11/3 |
WinXBIO / S&P 12.04% / -0.76% |
LoseXBIO / S&P XBIO unavailable / 7.68% |
LoseXBIO / S&P XBIO unavailable / 12.46% |
| 2017-Q40/3 |
LoseXBIO / S&P -5.00% / 6.64% |
LoseXBIO / S&P XBIO unavailable / 7.03% |
LoseXBIO / S&P XBIO unavailable / 13.82% |
| 2017-Q30/3 |
LoseXBIO / S&P -26.81% / 4.48% |
LoseXBIO / S&P XBIO unavailable / 5.68% |
LoseXBIO / S&P XBIO unavailable / 17.57% |
| 2017-Q20/3 |
LoseXBIO / S&P -39.34% / 3.09% |
LoseXBIO / S&P XBIO unavailable / 4.83% |
LoseXBIO / S&P XBIO unavailable / 17.74% |
| 2017-Q10/3 |
LoseXBIO / S&P 5.81% / 6.07% |
LoseXBIO / S&P XBIO unavailable / 3.67% |
LoseXBIO / S&P XBIO unavailable / 13.32% |
| 2016-Q40/3 |
LoseXBIO / S&P -4.44% / 3.82% |
LoseXBIO / S&P XBIO unavailable / 2.09% |
LoseXBIO / S&P XBIO unavailable / 7.05% |
| 2016-Q30/3 |
LoseXBIO / S&P -11.76% / 3.85% |
LoseXBIO / S&P XBIO unavailable / 0.20% |
LoseXBIO / S&P XBIO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | XBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 39.30% | 20.78% |
| Annualized return | 39.30% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | XBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -86.36% | 83.14% |
| Annualized return | -32.86% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | XBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.34% | 319.30% |
| Annualized return | -39.52% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |